Indium (In-111) Chloride Curium (Indium (111in))

Indium-111 emits gamma photons that can be detected by a gamma camera. When attached to antibodies, peptides or a patient’s own white blood cells, the radionuclide travels to specific tissues based on biological affinity, allowing the emitted photons to create high‑resolution images of the targeted area.

The administered activity of Indium-111 chloride is determined by the prescribing physician or nuclear medicine specialist. Dosing is individualized according to the specific diagnostic indication, the labeling method used and the patient’s body weight or surface area, and follows local regulatory guidelines.

Data on the safety of Indium-111 chloride in pregnant or lactating women are limited. Because the agent delivers ionising radiation, it is generally avoided unless the diagnostic benefit clearly outweighs the potential risk to the fetus or infant. Consultation with a radiology and obstetrics specialist is essential.

To request Indium-111 chloride, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Compared with commonly used Technetium‑99m agents, Indium-111 offers a longer half‑life (≈2.8 days) and higher energy gamma emissions, which can be advantageous for delayed imaging and cell labeling. However, its higher radiation dose and need for specialized gamma cameras may limit use to specific clinical scenarios where its unique properties are required.

Indium-111 chloride must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. The product should be handled in a shielded environment by trained personnel, and all waste must be managed according to local radiation safety regulations.

The radiopharmaceutical is supplied as an injectable solution and is administered intravenously by a qualified nuclear medicine professional. Depending on the clinical protocol, it may be given directly or used to label cells or compounds that are then re‑injected for imaging.

The most serious risks include severe allergic reactions such as anaphylaxis, radiation‑induced tissue injury at high‑dose sites, and hematologic toxicity leading to significant reductions in blood cell counts. Prompt recognition and appropriate medical management are essential if any of these events occur.

Patients with a known hypersensitivity to Indium‑111 or any component of the formulation should avoid the product. It is also contraindicated in pregnant women unless absolutely necessary, in individuals with severe renal impairment without dose adjustment, and in patients who have recently received other high‑dose radiopharmaceuticals.